ES2082872T3 - Composiciones antiglaucoma que contienen 3-arilcarbonil-1-aminoalquil--1h-indol. - Google Patents

Composiciones antiglaucoma que contienen 3-arilcarbonil-1-aminoalquil--1h-indol.

Info

Publication number
ES2082872T3
ES2082872T3 ES91103425T ES91103425T ES2082872T3 ES 2082872 T3 ES2082872 T3 ES 2082872T3 ES 91103425 T ES91103425 T ES 91103425T ES 91103425 T ES91103425 T ES 91103425T ES 2082872 T3 ES2082872 T3 ES 2082872T3
Authority
ES
Spain
Prior art keywords
aminoalkyl
aryl carbonyl
compositions containing
indol
antiglaucoma compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91103425T
Other languages
English (en)
Inventor
Susan Jean Ward
Malcolm Rice Bell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
STWB Inc
Original Assignee
Sterling Winthrop Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sterling Winthrop Inc filed Critical Sterling Winthrop Inc
Application granted granted Critical
Publication of ES2082872T3 publication Critical patent/ES2082872T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSICIONES ANTIGLAUCOMA QUE CONTIENEN 3-ARILCARBONILO-1-AMINOALQUILO-1H-INDOLES, COMO SU COMPONENTE ACTIVO, Y UN METODO DE SU USO EN EL TRATAMIENTO DEL GLAUCOMA. TAMBIEN SE INCLUYEN NUEVOS 3-ARILCARBONILO-1-AMINOALQUILO-1H-INDOLES.
ES91103425T 1990-03-08 1991-03-06 Composiciones antiglaucoma que contienen 3-arilcarbonil-1-aminoalquil--1h-indol. Expired - Lifetime ES2082872T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49020190A 1990-03-08 1990-03-08

Publications (1)

Publication Number Publication Date
ES2082872T3 true ES2082872T3 (es) 1996-04-01

Family

ID=23947024

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91103425T Expired - Lifetime ES2082872T3 (es) 1990-03-08 1991-03-06 Composiciones antiglaucoma que contienen 3-arilcarbonil-1-aminoalquil--1h-indol.

Country Status (21)

Country Link
EP (1) EP0445781B1 (es)
JP (1) JP3157179B2 (es)
KR (1) KR0183396B1 (es)
AT (1) ATE133663T1 (es)
AU (1) AU643757B2 (es)
CA (1) CA2036307C (es)
DE (1) DE69116705T2 (es)
DK (1) DK0445781T3 (es)
ES (1) ES2082872T3 (es)
FI (1) FI95369C (es)
GR (1) GR3019058T3 (es)
HU (1) HU215125B (es)
IE (1) IE72953B1 (es)
IL (1) IL97426A (es)
MX (1) MX174433B (es)
MY (1) MY106109A (es)
NO (1) NO179612C (es)
NZ (1) NZ237309A (es)
PH (1) PH27022A (es)
PT (1) PT96938B (es)
RU (1) RU2073670C1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5068234A (en) * 1990-02-26 1991-11-26 Sterling Drug Inc. 3-arylcarbonyl-1-(c-attached-n-heteryl)-1h-indoles
GB9204365D0 (en) * 1992-02-28 1992-04-08 Pfizer Ltd Indoles
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
FR2713224B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
ES2099007B1 (es) * 1993-07-16 1997-12-01 Pfizer Res & Dev Derivados de indol.
FR2714057B1 (fr) * 1993-12-17 1996-03-08 Sanofi Elf Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.
NZ507391A (en) * 1998-05-01 2003-12-19 Lilly Co Eli The compound ((3-(2-amino-1,2-dioxoethyl)-2-methyl-1- (phenylmethyl)-1H-indol-4-yl)oxy)acetic acid N-morpholino ethyl ester and its use as a sPLA 2 inhibitor
DK0985414T3 (da) * 1998-05-26 2003-12-29 Pfizer Prod Inc Lægemiddel til behandling af glaukome og iskæmisk retinopati
AU2042301A (en) * 1999-12-03 2001-06-12 Alcon Universal Limited 1-aminoalkyl-1H-indoles for treating glaucoma
DE60135972D1 (de) * 2000-01-18 2008-11-13 Merck & Co Inc Orhthalmologische zusammenstellungen zur behandlung von ocularer hypertension
EP1254115A2 (en) * 2000-02-11 2002-11-06 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
TWI231757B (en) * 2001-09-21 2005-05-01 Solvay Pharm Bv 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
AR038966A1 (es) * 2002-03-18 2005-02-02 Solvay Pharm Bv Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1
SE0203070D0 (en) 2002-10-16 2002-10-16 Astrazeneca Ab Novel compounds
TW200508197A (en) 2003-03-31 2005-03-01 Ucb Sa Indolone-acetamide derivatives, processes for preparing them and their uses
KR20070012389A (ko) * 2004-03-05 2007-01-25 악조 노벨 엔.브이. 칸나비노이드 ｃｂ1 수용체의 아고니스트로서의(인돌-3-일)-헤테로시클 유도체
DE602006015309D1 (de) * 2005-03-12 2010-08-19 Unilever Nv Haar- und/oder kopfhautpflegezusammensetzungen mit amino-oxo-indolyliden-verbindungen
FR2893615B1 (fr) * 2005-11-18 2008-03-07 Sanofi Aventis Sa Derives de 3-acylindole, leur preparation et leur application en therapeutique
RU2404185C1 (ru) * 2009-04-16 2010-11-20 Учреждение Российской академии наук Институт молекулярной генетики РАН (ИМГ РАН) РАВНОМЕРНО МЕЧЕННЫЙ ТРИТИЕМ (R)-(+)-[5-МЕТИЛ-3-(4-МОРФОЛИНИЛМЕТИЛ)-2,3-ДИГИДРО-[1,4]ОКСАЗИНО [2,3,4-hi]-6-ИНДОЛИЛ]-1-НАФТАЛИНИЛМЕТАНОН АЦЕТАТ
JP6025234B1 (ja) * 2016-03-10 2016-11-16 株式会社サンライフ 箸における箸置き形成方法及び箸置き機能を有する箸
CN107628981B (zh) * 2017-10-31 2019-07-30 威海市妇女儿童医院 一种肉桂酰基吲哚啉化合物及其制备青光眼药物的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1436771A (en) * 1973-02-16 1976-05-26 Labaz Indole derivatives and process for preparing the same
US4581354A (en) * 1984-08-06 1986-04-08 Sterling Drug Inc. 3-arylcarbonyl- and 3-cycloalkylcarbonyl-1-aminoalkyl-1H-indoles, compositions and use
US4634776A (en) * 1984-08-06 1987-01-06 Sterling Drug, Inc. 3-arylcarbonyl-and 3-cycloalkylcarbonyl-1-aminoalkyl-1H-indoles
US4634698A (en) * 1984-09-24 1987-01-06 Schering Corporation Antiglaucoma agents
DE3821148A1 (de) * 1988-06-23 1989-12-28 Erwin Von Dr Angerer Aminoalkylindole, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate

Also Published As

Publication number Publication date
EP0445781B1 (en) 1996-01-31
FI95369C (fi) 1996-01-25
KR0183396B1 (ko) 1999-05-01
PT96938A (pt) 1991-10-31
JPH04235164A (ja) 1992-08-24
FI911131L (fi) 1991-09-09
RU2073670C1 (ru) 1997-02-20
HU215125B (hu) 1998-09-28
HUT56492A (en) 1991-09-30
PH27022A (en) 1993-02-01
NO910868L (no) 1991-09-09
EP0445781A1 (en) 1991-09-11
IE72953B1 (en) 1997-05-07
DE69116705T2 (de) 1996-09-26
IE910700A1 (en) 1991-09-11
JP3157179B2 (ja) 2001-04-16
MX24839A (es) 1993-10-01
PT96938B (pt) 1998-07-31
MX174433B (es) 1994-05-16
CA2036307C (en) 2002-07-09
GR3019058T3 (en) 1996-05-31
NO179612B (no) 1996-08-05
DK0445781T3 (da) 1996-02-19
FI95369B (fi) 1995-10-13
ATE133663T1 (de) 1996-02-15
NO910868D0 (no) 1991-03-05
AU643757B2 (en) 1993-11-25
NZ237309A (en) 1993-02-25
AU7266991A (en) 1991-09-12
NO179612C (no) 1996-11-13
FI911131A0 (fi) 1991-03-06
IL97426A (en) 1996-03-31
MY106109A (en) 1995-03-31
KR910016745A (ko) 1991-11-05
DE69116705D1 (de) 1996-03-14
IL97426A0 (en) 1992-06-21
CA2036307A1 (en) 1991-09-09

Similar Documents

Publication Publication Date Title
ES2082872T3 (es) Composiciones antiglaucoma que contienen 3-arilcarbonil-1-aminoalquil--1h-indol.
ES2074867T3 (es) Derivados de quinazolina para potenciar la actividad antitumoral.
ES2157027T3 (es) Oxazolidinonas sustituidas y su uso como farmacos antibacterianos.
ES2122043T3 (es) Nuevos derivados sustituidos del pirazol, procedimientos para su preparacion y su empleo como herbicidas.
ES2167377T3 (es) Derivados de piridina farmacologicamente activos y procedimientos para la preparacion de los mismos.
ES2186783T3 (es) Derivados de la dolastatina, su preparacion y uso.
ES2077869T3 (es) Policitraconimidas y poliitaconimidas que contienen poli(sulfuro).
ES2154262T3 (es) Uso de compuestos macrolidos para enfermedades oculares.
UY24006A1 (es) Derivado del 2-(2-amino -1,6-dihidro-6-oxo-purin-9-il)metoxil-1,3-propanodiol.
ES2061118T3 (es) N-oxidos de piridinas sustituidas en posiciones 2,4 y 2,5, procedimiento para su preparacion, asi como su utilizacion.
ES2108129T3 (es) Nuevos derivados de pirazina, su preparacion y empleo.
ES2072784T3 (es) Benzo- y piridopiridonas substituidas con sulfonilbencilo.
ES2152016T3 (es) Solucion oftalmica de pranoprofeno conteniendo amina organica.
ES2100689T3 (es) Asociacion sinergizante que tiene un efecto antagonista de los receptores nk1 y nk2.
ES2096743T3 (es) Nuevas composiciones.
AR004474A1 (es) Compuestos de 10-aminoalifatil-dibenz [b,f]oxepinas antineurodegenerativamente activas, utiles para el tratamiento de estados neurodegenerativos y composiciones farmaceuticas que los contienen
ES2022192B3 (es) Eteres de oximas sustituidos, su utilizacion como biorreguladores para la reduccion del nivel de etileno endogeno en las plantas.
ES2164858T3 (es) Colorantes reactivos, obtencion y uso de los mismos.
DE69106777D1 (de) Behandlung von intraokularem Druck mit einer ophthalmischen synergistischen Kombination.
ES2156212T3 (es) Derivados de azabicicloheptano n-substituidos como neurolepticos, etc.
ES2153584T3 (es) Piridiniminil-1,2-benzisoxazol y -benzisotiazol como antipsicoticos.
ES2118818T3 (es) Tiazolin-2-onas aminoalquil-substituidas, su obtencion y empleo.
ES2151891T3 (es) Derivados de ciclohexano sustituidos con imidazolilo.
ES2124267T3 (es) Derivados macrolidas de 16 eslabones con una actividad antibacteriana prolongada en el plasma, intermediarios de sintesis y procedimiento de preparacion.
ES2062024T3 (es) Nuevo pentapeptido y un procedimiento para su preparacion.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 445781

Country of ref document: ES